Journal of Clinical Oncology
Articles in this Issue
Identification of novel electrophysiologic biomarkers of cognition in glioma-infiltrated cortex.
2077 Background: Diffuse gliomas, the most common primary brain cancers, often invade speech-critical areas. Maximal resection improves survival, but dama...
Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors: Does age matter?
4124 Background: While age is not an independent risk factor for poor outcomes it can have significant influence on outcomes in HCC. The median age of dia...
Efficacy and safety of trastuzumab deruxtecan in HER2+ and HER2-low metastatic breast cancer: Real-world data from India.
e13023 Background: Trastuzumab deruxtecan (T-DXd) is a transformative therapy for HER2+ and HER2-low metastatic breast cancer (MBC). However, real-world d...
PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor a (PPARα) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.
TPS4214 Background: PPARα is a fatty acid ligand-activated transcription factor that regulates genes involved in fatty acid oxidation (FAO), angiogenesis,...
International medical graduates (IMGs) in leadership roles within academic oncology in the United States (US).
9004 Background: Although IMGs comprise one-third of US oncologists, their leadership presence at academic centers with affiliated oncology fellowship tra...
Phase I study of sustained and local delivery of intraperitoneal IL-2 using encapsulated cells in patients with platinum-resistant high-grade serous carcinoma.
5562 Background: Platinum-resistant high-grade serous carcinoma's (HGSC) propensity to metastasize throughout the peritoneal cavity has generated interest...
Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402).
TPS8113 Background: There are currently three approved approaches for patients with resectable NSCLC including neoadjuvant chemoimmunotherapy, adjuvant ch...
Efficacy and safety of liposomal irinotecan combined with cadonilimab as second-line treatment for extensive-stage small cell lung cancer (ES-SCLC): A prospective, single arm phase II clinical study.
e20104 Background: ES-SCLC proliferates rapidly and has a poor prognosis. 60% -70% of SCLC patients (pts) are diagnosed as ES-SCLC. At present, the availa...
Fibroblast growth factor receptor 3 ( <i>FGFR3</i> ) alteration status and outcomes with immune checkpoint inhibitors (ICPI) in patients with metastatic urothelial carcinoma.
4564 Background: The use of immune checkpoint inhibitors (ICPIs) has expanded in the treatment of metastatic urothelial carcinoma (mUC) but response rates...
Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial.
7000 Background: The prognostic utility of circulating tumor DNA measurable residual disease (ctDNA-MRD) detection at end of treatment (EOT) using phased...
A phase Ib study of a pooled synthetic long peptide mutant KRAS vaccine combined with balstilimab/botensilimab in metastatic pancreatic cancer and metastatic MMR-proficient colorectal cancer in the maintenance setting.
TPS2698 Background: Expressed in > 90% of all patients with pancreatic ductal adenocarcinoma (PDAC) and ~40% in mismatch repair-proficient colorectal c...
The potential of multi-cancer early detection screening in reducing cancer incidence and mortality in high-risk groups: A modeling study.
10542 Background: Emerging liquid biopsy multi-cancer early detection (MCED) tests have the potential to revolutionize early cancer detection. Using a sim...
Circulating tumor DNA-based genomic profiling and real-world outcomes in cancer of unknown primary (CUP).
4200 Background: CUP accounts for <5% of cancers and carries a dismal prognosis with median overall survival of ~13 months. Studies suggest up to one-t...
Assessing the value of multiple molecular tumor board reviews for sequential next-generation sequencing in patients with solid-tumor malignancies.
e23340 Background: Multi-disciplinary molecular tumor boards (MTB) are shown to improve clinical outcomes in various malignancies. Sequential next-generat...
Matching-adjusted indirect comparison (MAIC) of olutasidenib (OLU) and ivosidenib (IVO) in isocitrate dehydrogenase 1 (IDH1)-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML).
6546 Background: OLU and IVO are allosteric type II IDH1 inhibitors approved by the FDA and recommended by NCCN for IDH1...
Single center experience with neoadjuvant chemoimmunotherapy versus chemotherapy in patients with high-risk early stage triple negative breast cancer.
e12617 Background: The addition of immunotherapy to neoadjuvant chemotherapy (NAC) has become standard of care for high-risk early-stage triple negative b...
Trends and disparities in liver cell carcinoma and hepatic failure–related mortality in the US: A retrospective analysis.
e23101 Background: Liver cell carcinoma (LCC) and hepatic failure (HF) are major contributors to global adult mortality. Identifying trends and disparitie...
Performance evaluation of a reflex blood-based methylated ctDNA multi-cancer early detection test in individuals with obesity.
100 Background: Obesity increases risk of 13 distinct cancers, most without screening programs, and collectively representing 40% of all annual US cancer...
Long-term survival outcomes of pseudoadjuvant chemotherapy for resectable metastatic colon cancer: A 14-year single-center experience from King Fahad Medical City, Saudi Arabia.
e15511 Background: Standard treatment for resectable Stage II-III colon cancer typically involves surgery followed by adjuvant chemotherapy for 3-6 months...
Imaging with [ <sup>89</sup> Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with neuroendocrine tumors of the prostate: A phase 1/2, first-in-human trial.
e15057 Background: Delta-like ligand 3 (DLL3) is expressed on the tumor cell surface of some neuroendocrine prostate cancer (NEPC). We assessed the safety...
A phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.
TPS3167 Background: B7-H4 is a transmembrane receptor of the B7-family of immunomodulatory proteins whose expression correlates with poor clinical outcome...
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.
502 Background: Current treatment de-escalation strategies in HER2+ early breast cancer (eBC) aim to mitigate acute and late toxicities by reducing or ent...
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study.
3014 Background: No globally approved therapies exist for adults with NF1 and symptomatic, inoperable PN.KOMET is evaluating the efficacy and safety of se...
Treatment patterns, genomic characteristics, and outcomes among patients with metastatic lobular breast cancer.
1119 Background: Invasive lobular carcinoma (ILC) is characterized by loss of E-cadherin expression and accounts for 10-15% of breast cancer diagnoses. IL...
IT-IO: Intrathecal administration of nivolumab and ipilimumab in combination with systemic combination of nivolumab and ipilimumab in patients with non-small cell lung cancer or melanoma and newly diagnosed leptomeningeal metastasis, a multicentric phase I study.
2029 Background: The optimal management of patients with leptomeningeal metastases (LM) from non-small cell lung cancer (NSCLC) or melanoma remains contro...